ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Zirconium Zr 89 Girentuximab

Also written as “89Zr-TLX250 PET/CT” and “89Zr-Girentuximab”.

Its studies are mostly in Carcinoma, Renal Cell, led by Telix Pharmaceuticals.

Drug pageZirconium Zr 89 Girentuximab: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 26, 20242 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Telix Pharmaceuticals21 open or runningphase 3since Nov 26, 2024Apr 5, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 5, 2023First study: phase 1 study in Carcinoma, Renal CellFirst studyNCT05861778 · 10 enrolled · China
  2. Nov 26, 2024Phase 3 study in Carcinoma, Renal CellNCT06750419 · 82 planned · China

TargetBeta

CA9 →read by rule
“A radioimmunoconjugate comprised of the recombinant chimeric monoclonal antibody girentuximab, that binds an extracellular epitope of carbonic anhydrase IX (CAIX), and ”NCIt, by rule

Other programs on CA9

ProgramCompanyFurthest phaseStudies
sulthiameruleShionogiphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06750419Carcinoma, Renal Cell · China3RecruitingJun 30, 202682
NCT05861778Carcinoma, Renal Cell · China1CompletedNov 27, 202310

How it is read

Names in the registry

  • “89Zr-TLX250 PET/CT”, 1 entry
  • “89Zr-Girentuximab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.